Overview
- Hims will begin offering FDA-approved Ozempic injections and Wegovy injections and pill to U.S. patients later this month at the same self-pay prices available on other telehealth channels.
- Hims will stop advertising compounded GLP-1 products and keep them only for cases a clinician deems clinically necessary, with current users able to transition to branded options.
- Novo dismissed its patent-infringement case tied to Hims’ short-lived $49 compounded semaglutide pill and reserved the right to refile in the future.
- Regulatory pressure formed a key backdrop as the FDA recently warned telehealth companies about misleading promotion of compounded GLP-1 drugs not equivalent to approved medicines.
- Hims shares jumped roughly 40%–55% after the announcement, while Novo highlighted recent price cuts to $149–$299 per month and reported 600,000+ Wegovy pill prescriptions since launch.